title: Augmentation of platelet and endothelial cell eNOS activity decreases sepsis-related neutrophil-endothelial cell interactions.
abstract: NO is an important mediator of microvascular patency and blood flow. The purpose of this study was to examine the role of enhanced eNOS activity in attenuating sepsis-induced neutrophil-endothelial cell interactions. Microslides coated with human umbilical vein endothelial cells were stimulated with plasma from patients with septic shock. Neutrophil and platelets from control subjects were also stimulated with plasma from patients in septic shock and perfused over stimulated endothelial cells. l-Arginine (LA) with and without NG-monomethyl l-arginine (LNMMA), a nonselective NOS inhibitor, and N-(3-(aminomethyl) benzyl acetamide) ethanimidamide dihydrochloride (1400W), a highly selective iNOS inhibitor, were added to the septic plasma. The number of neutrophils adherent to endothelial cells, neutrophil rolling velocity, and the number of neutrophil aggregates were determined. Cell activation and the formation of platelet-neutrophil aggregates were assessed by flow cytometry. Separate experiments were done with isolated platelets using platelet aggregometry. l-Arginine significantly decreased sepsis-related neutrophil adhesion and aggregation and increased rolling velocity. The addition of LNMMA to LA and cell suspensions reversed the effects of LA on these parameters, whereas the addition of 1400W had no effect on LA-related changes. Platelet-neutrophil aggregation, platelet aggregation, platelet activation, and neutrophil activation induced by septic plasma were also significantly decreased by LA. Again, the addition of LNMMA reversed the effects of LA on these parameters, whereas 1400W had no effect on LA-related changes. These data suggest that enhancement of platelet and endothelial cell eNOS activity decreases sepsis-induced neutrophil-endothelial cell interactions and may play a role in maintaining microvascular patency in septic shock.
authors.affiliation: Department of Medicine, New York Medical College, Valhalla, NY, USA.
authors.forename: Raymond
authors.initials: R
authors.lastname: Khan
authors.forename: Linda A
authors.initials: LA
authors.lastname: Kirschenbaum
authors.forename: Catherine
authors.initials: C
authors.lastname: LaRow
authors.forename: Gioiamaria
authors.initials: G
authors.lastname: Berna
authors.forename: Kelly
authors.initials: K
authors.lastname: Griffin
authors.forename: Mark E
authors.initials: ME
authors.lastname: Astiz
mesh_terms: D000328:Adult; D000368:Aged; D001120:Arginine / Q000494:pharmacology; D042783:Endothelial Cells / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007097:Imines / Q000494:pharmacology*; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism*; D015539:Platelet Activation / Q000187:drug effects; D010974:Platelet Aggregation; D012772:Shock, Septic / Q000503:physiopathology*; D019323:omega-N-Methylarginine / Q000494:pharmacology
chemical_list: D007097:Imines; C496401:N-((3-(aminomethyl)phenyl)methyl)ethanimidamide; D019323:omega-N-Methylarginine; D001120:Arginine; C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III